Haya Therapeutics Closes CHF 18M Funding
- Haya Therapeutics, a Lausanne, Switzerland-based company which develops precision medicines that target tissue and cell-specific long non-coding RNAs, closed a CHF18M funding round
- The round was led by Broadview Ventures, with participation from Apollo Health Ventures, Bernina BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator
- The company intends to use the funds to advance the discovery and development of innovative organ and cell-selective therapeutics
- The company develops precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs)
- Haya is preparing to initiate clinical trials with its Wisper targeting candidate in non-obstructive hypertrophic cardiomyopathy, an orphan indication with limited treatment options
- The company secured an exclusive license from CHUV for the Wisper asset
